Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

Phase I data reported for angiogenesis inhibitor TAS-115

June 9, 2015

EC-1456 generally well tolerated in phase I trial

June 9, 2015

AYX-2 transcription factor decoy shows potential for the treatment of chronic pain

June 9, 2015

Encouraging phase II data reported for selinexor in gynecological malignancies

June 8, 2015

Scientists disclose phase I results for G-305

June 8, 2015

ATF6 may have a relevant role in the development of achromatopsia

June 8, 2015

Phase III study finds biosimilar BCD-021 equivalent to Avastin in NSCLC

June 8, 2015

ABT-414 shows potential for the treatment of solid tumors

June 5, 2015

ONO-2952, a TSPO antagonist for IBS-D: RESTORE-4 phase II clinical results

June 5, 2015

Sustained responses seen with LY-2951742 in migraineurs

June 5, 2015

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 9, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...